Susanne Herndlhofer

Susanne Herndlhofer

UNVERIFIED PROFILE

Are you Susanne Herndlhofer?   Register this Author

Register author
Susanne Herndlhofer

Susanne Herndlhofer

Publications by authors named "Susanne Herndlhofer"

Are you Susanne Herndlhofer?   Register this Author

20Publications

1138Reads

45Profile Views

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1+ clones in TKI-resistant CML.

EBioMedicine 2019 Dec 21;50:111-121. Epub 2019 Nov 21.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Ludwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.11.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921367PMC
December 2019

Phenotyping and Target Expression Profiling of CD34/CD38 and CD34/CD38 Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Neoplasia 2018 06 15;20(6):632-642. Epub 2018 May 15.

Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2018.04.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994777PMC
June 2018

The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia.

Br J Haematol 2018 04 21;181(1):137-139. Epub 2017 Feb 21.

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.14508
Publisher Site
http://dx.doi.org/10.1111/bjh.14508DOI Listing
April 2018

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.

Am J Hematol 2016 12 8;91(12):1239-1245. Epub 2016 Nov 8.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24560DOI Listing
December 2016

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Clin Cancer Res 2016 Apr 25;22(8):2051-61. Epub 2015 Nov 25.

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria. Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0767DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817228PMC
April 2016

Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

Am J Cancer Res 2015 15;5(1):354-62. Epub 2014 Dec 15.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna Vienna, Austria ; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300686PMC
January 2015

Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.

Clin Cancer Res 2014 Jul 5;20(13):3589-602. Epub 2014 May 5.

Authors' Affiliations: Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2811DOI Listing
July 2014

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Am J Hematol 2011 Jul 27;86(7):533-9. Epub 2011 Apr 27.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.22037DOI Listing
July 2011

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

Haematologica 2011 Jan 7;96(1):163-6. Epub 2010 Oct 7.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2010.030494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012781PMC
January 2011

Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML.

Eur J Intern Med 2009 Dec 7;20(8):775-8. Epub 2009 Oct 7.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejim.2009.09.007DOI Listing
December 2009